Nothing Special   »   [go: up one dir, main page]

CA2896174A1 - Charpente d'anticorps pour greffe de cdr - Google Patents

Charpente d'anticorps pour greffe de cdr Download PDF

Info

Publication number
CA2896174A1
CA2896174A1 CA2896174A CA2896174A CA2896174A1 CA 2896174 A1 CA2896174 A1 CA 2896174A1 CA 2896174 A CA2896174 A CA 2896174A CA 2896174 A CA2896174 A CA 2896174A CA 2896174 A1 CA2896174 A1 CA 2896174A1
Authority
CA
Canada
Prior art keywords
immunobinder
framework
antibody
heavy chain
acceptor framework
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2896174A
Other languages
English (en)
Inventor
Dominik Escher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esbatech a Novartis Co LLC
Original Assignee
Esbatech a Novartis Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech a Novartis Co LLC filed Critical Esbatech a Novartis Co LLC
Publication of CA2896174A1 publication Critical patent/CA2896174A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2896174A 2013-02-20 2013-02-20 Charpente d'anticorps pour greffe de cdr Abandoned CA2896174A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/053329 WO2014127811A1 (fr) 2013-02-20 2013-02-20 Charpente d'anticorps pour greffe de cdr

Publications (1)

Publication Number Publication Date
CA2896174A1 true CA2896174A1 (fr) 2014-08-28

Family

ID=47740957

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2896174A Abandoned CA2896174A1 (fr) 2013-02-20 2013-02-20 Charpente d'anticorps pour greffe de cdr

Country Status (8)

Country Link
EP (1) EP2958939A1 (fr)
JP (1) JP2016506752A (fr)
CN (1) CN104884471A (fr)
AU (1) AU2013379444A1 (fr)
CA (1) CA2896174A1 (fr)
HK (1) HK1219485A1 (fr)
RU (1) RU2015139890A (fr)
WO (1) WO2014127811A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3288973B1 (fr) * 2015-04-30 2021-10-20 AbCheck s.r.o. Procédé d'humanisation en masse d'anticorps de lapin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0832981A1 (fr) 1987-02-17 1998-04-01 Pharming B.V. Séquences d'ADN pour diriger des protéines vers les glandes mammaires, afin d'être secrétées efficacement
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
CA2126967A1 (fr) 1992-11-04 1994-05-11 Anna M. Wu Nouvelle construction d'anticorps
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6905668B1 (en) 1998-09-25 2005-06-14 Tokyo Gas Company Limited Diagnostic agents for pancreatic exocrine function
WO2001048017A1 (fr) 1999-12-28 2001-07-05 Esbatech Ag Intracorps a charpente definie stable dans un environnement reducteur et leurs applications
US20040220388A1 (en) 2000-06-30 2004-11-04 Nico Mertens Novel heterodimeric fusion proteins
HUE048922T2 (hu) * 2002-05-22 2020-09-28 Novartis Ag Immunglobulin vázrégiók, amelyek intracelluláris környezetben fokozott stabilitást mutatnak, továbbá eljárások azonosításukra
EP1539947A4 (fr) 2002-08-15 2006-09-06 Epitomics Inc Anticorps humanises de lapin
CA2533830A1 (fr) 2003-08-07 2005-02-24 Epitomics, Inc. Methodes destinees a humaniser des anticorps monoclonaux de lapin
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
WO2008144757A1 (fr) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Nouveaux procédés d'humanisation d'anticorps de lapin et anticorps de lapin humanisés
WO2008144753A2 (fr) * 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Anticorps anti-tnf alpha et leur utilisation
EP3241843B1 (fr) * 2008-06-25 2021-07-28 Novartis AG Optimisation de solubilité d'agents de liaison immunologique
BRPI0914663A2 (pt) * 2008-06-25 2015-10-20 Esbatech Alcon Biomed Res Unit humanização de anticorpos de coelho usando uma estrutura de anticorpo universal
US8399624B1 (en) * 2009-06-25 2013-03-19 Esbatech, An Alcon Biomedical Research Unit Llc Acceptor framework for CDR grafting

Also Published As

Publication number Publication date
CN104884471A (zh) 2015-09-02
WO2014127811A1 (fr) 2014-08-28
EP2958939A1 (fr) 2015-12-30
JP2016506752A (ja) 2016-03-07
HK1219485A1 (zh) 2017-04-07
AU2013379444A1 (en) 2015-06-11
RU2015139890A (ru) 2017-03-27

Similar Documents

Publication Publication Date Title
US20200362059A1 (en) Acceptor Framework for CDR Grafting
US11858981B2 (en) Humanization of rabbit antibodies using a universal antibody framework
CA2894918A1 (fr) Structure d'accepteur pour greffe cdr
CA2896174A1 (fr) Charpente d'anticorps pour greffe de cdr
CA2728004C (fr) Humanisation d'anticorps de lapins au moyen d'une infrastructure d'anticorps universelle
AU2020201002B2 (en) Humanization of rabbit antibodies using a universal antibody framework
AU2013203004B2 (en) Humanization of rabbit antibodies using a universal antibody framework
KR102284435B1 (ko) 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190220